Evidence map›Paper›PMID 41870851›Full record

ReviewNeurology and therapy2026

Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway.

Cecilia Smith Simonsen, Marton König, Stein Henry Bjelland, Hilde-Marie Andersen, Tobias Dugstad, Øivind Torkildsen

Abstract readReview
In one paragraph

Review in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cecilia Smith SimonsenNeurological Department, Drammen Hospital, Vestre Viken Health Trust, Drammen, Norway. cecsim@vestreviken.no.
Marton KönigDepartment of Neurology, Oslo University Hospital, Oslo, Norway.
Stein Henry BjellandVestfold Hospital Trust, Tønsberg, Norway.
Hilde-Marie AndersenMerck AS, Oslo, Norway, an Affiliate If Merck KGaA.
Tobias DugstadDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Øivind TorkildsenDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapsing multiple sclerosis (RMS) is most often diagnosed in young adulthood but may also manifest during childhood or later in life. The number of older people living with RMS (pwMS) continues to grow as life expectancy increases and MS incidence rises among older adults. This review summarises the principal challenges in managing pwMS at different stages of life. Paediatric-onset RMS: RMS onset in childhood and adolescence is typically characterised by a higher relapse rate. Early diagnosis, timely intervention, and specialised care are essential. Management also requires close collaboration among healthcare providers, families, and educational institutions to help children balance the disease burden with academic, social, and family life. Young adults with RMS: In young adulthood, MS can disrupt education, employment, relationships, and family planning. Individualised treatment strategies and shared decision-making are essential to align disease management with evolving personal and professional goals. Older pwMS: Age-related issues such as immunosenescence, disability progression, comorbidities, polypharmacy, and menopause become increasingly relevant. Vaccination is particularly important given both immunomodulatory therapies and reduced immune resilience associated with immunosenescence. As pwMS age, treatment strategies may include disease-modifying therapy (DMT) de-escalation, discontinuation, or immune reconstitution therapies to reduce long-term immunosuppression. In conclusion, a holistic, pwMS-centred approach is essential to tailor MS management across the lifespan, adjusting to the medical, functional, and psychosocial needs of pwMS at each stage of life.

Indexed as

AgeDisease-modifying therapyMultiple sclerosisPatient-centred care

Identifiers

PMID41870851
PMCPMC13172067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.